A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is
In this abstract we review the pancreatic cancer epigenetic mark up and the impact of related therapies on preclinical and clinical outcome. We explore the potentials of combination therapies with targeted drugs in a protocol called multitargeted epigenetic therapies (MTET) with a specific focus on intratumoral hypoxia and angiogenesis. We share our invitro data as well as a review of case studies of advanced pancreatic cancer treated with such protocol and we conclude that such combinationdoi:10.15761/cmr.1000149 fatcat:vj7u2yokcrhhjcmm4gjd5766bq